AI
Last year, Biotechs were hot. This year, the sector is not. But there are good companies that are down 70% to 80% NOT because they are not promising companies, but because the sector is out of favor and positive developments are not rewarded with higher prices.
But this trend may end soon.
Did some due diligence on the following stocks. All down big, but with real opportunity to advance their clinical trials.
Fortress Biotech (FBIO)
Inhibikase Therapeutics (IKT)
Curative Biotechnology (CUBT)
First two are on NASDAQ. CUBT on the pinks--but is included on the list due to a recently announcement agreement with the NIH to conduct clinical trials on their Macular Degeneration treatment.
But this trend may end soon.
Did some due diligence on the following stocks. All down big, but with real opportunity to advance their clinical trials.
Fortress Biotech (FBIO)
Inhibikase Therapeutics (IKT)
Curative Biotechnology (CUBT)
First two are on NASDAQ. CUBT on the pinks--but is included on the list due to a recently announcement agreement with the NIH to conduct clinical trials on their Macular Degeneration treatment.
Successful Trading is the art of minimizing long term risk and maximizing capital allocation.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
